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Abstract  
Objectives: APOL1 genetic variants contribute to kidney disease in African Americans (AA).  
We assessed correlations between APOL1 profiles and renal histological features in subjects 
without renal disease.  
Methods: Glomerular number (Nglom) and mean glomerular volume (Vglom) were measured 
by the disector/fractionator method in kidneys of AA and other Americans (non-AA) without 
renal disease, undergoing autopsies in Jackson, Mississippi.  APOL1 risk alleles were 
genotyped and the kidney findings were evaluated in the context of those profiles.   
Results:  In AA age >18 years, proportions with none, one and two APOL1 risk alleles were 
38%, 43% and 19% respectively.  38% had G1 allele variants and 31% had G2 allele variants.  
APOL1 positive AA appeared to have higher Nglom and smaller Vglom in early adult life, with  
reductions in Nglom and increases in Vglom with increasing age.   
Regressions predicted an annual average loss of 8,834 (p=0.033, sex adjusted) glomeruli per 
single kidney over the first 38 years of adult life in AA with two risk alleles.  BMIs above the 
group medians, (but below the “obesity” definition of >30 kg/m2) enhanced the expression 
of age-related changes in Nglom in AA with both one and two APOL1 risk alleles.       
Conclusions:  APOL1 risk alleles are associated with an exaggerated loss of nephrons with 
increasing age, probably decaying from a larger pool of smaller glomeruli in early adult life, 
along with enlargement of the remaining glomeruli.  
These phenomena might mark mechanisms of accentuated susceptibility to kidney disease 
in APOL1 positive AA.   
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Introduction 
Recent studies have shown that the accentuated risk of African Americans (AA) for renal 
disease is associated strongly with APOL1 risk alleles [1], with odds ratios of 7 for end-stage 
kidney disease attributed to hypertension [2], 17 for focal segmental glomerulosclerosis 
(FSGS) and 29 for HIV-associated nephropathy [3]. Conditions also associated with APOL1 
risk alleles include sickle nephropathy [4], collapsing HIV glomerulopathy [5,6] and with 
collapsing nephropathy and end-stage kidney disease associated with lupus nephritis [7,8] as 
well as increased allograft loss in deceased donor kidney transplants [9]. Further, the 
progression of chronic kidney disease (CKD) is more rapid in those with two APOL1 risk 
alleles, despite remittive therapy for FSGS and control of blood pressure for hypertension-
attributed CKD [2,3], with earlier institution of dialysis [10,11].  Furthermore, AA  without 
renal disease on enrolment in the community-based ARIC study were more likely to develop 
CKD and progress to ESRD on follow-up if they had had two APOL1 risk alleles, compared to 
those with no alleles or one allele [5].    Thus, APOL1 risk alleles increase the risk for 
progressive CKD when various injurious stimuli are present, and also predispose to the de 
novo development of CKD.    
The accentuated susceptibility of AA for kidney disease has been the focus of various 
hypotheses.  Brenner and colleagues proposed that reduced glomerular number, present at 
birth, predisposes to hypertension and CKD in adult life, and suggested that the increased 
susceptibility of AA for diabetic nephropathy might also be related to this phenomenon [12]. 
However, in prior studies from the Mississippi autopsy cohort, using an unbiased 
disector/fractionator stereological technique to count glomeruli, we did not find significantly 
lower total nephron numbers (Nglom) in AA than in European-Americans [13].   In that study 
we also found that while mean glomerular volume (Vglom) in AA was only marginally (and 
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non-significantly) larger in AA than in non-AA, the value was significantly larger in AA with 
hypertension than in those without [13,14,15]. Moreover, our studies on individual 
glomerular volumes (IGV) showed more size heterogeneity and net enlargement in AA than 
in non-AA [16,17,18]. 
The intent of the autopsy series in which this study is nested was to examine microanatomy 
in normal kidneys.  Here we describe histomorphometric phenotype in adult AA subjects in 
that series according to their APOL1 risk allele profiles.   
 
Results 
DNA was successfully extracted from formalin-fixed, paraffin-embedded tissue for 98% of AA 
and 99% of non-AA and genotyped for the two APOL1 renal risk missense variants 
comprising the G1 allele and the G2 insertion/deletion allele.  Of subjects, eighteen years 
and over, who were successfully genotyped (159 AA and 135 non-AA),   19% (30) of AA had 
two risk alleles, 43% (68) had one risk allele and 38% (61) had no risk alleles. More AA 
females than males tended to have 2 risk alleles than zero or one (p=0.022). Among non-AA, 
three people (2%) had a single APOL1 risk allele.   
As shown in Table 1, APOL1 genotype distributions and allele frequencies in AA were similar 
to those in a community-based sample of middle-aged AA, initially without renal disease, 
who were enrolled in the Atherosclerosis Risk in Community Study, ARIC [5]. As in the ARIC 
study, the genotypes in AA were in Hardy Weinberg equilibrium; although females had a 
slightly higher proportion of risk allele genotypes than expected, this was not significant.  
Table 2 shows some characteristics of subjects by race and number of APOL1 risk alleles. AA 
females with APOL1 risk alleles tended to be younger at time of death.  Females and males 
with two risk alleles tended towards lower weight, BMI and levels of obesity than other AAs.  
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However, only the younger ages at death for the dominant and additive models in females, 
and the lower levels of obesity for females with for the additive model were individually 
significant, and none of the associations were significant with Bonferroni adjustments for 
multiple tests.   
Figure 1 shows more detail on some of these associations, with adjustment for age. The data 
similarly suggest an additive model for lower BMI with increasing numbers of APOL1 risk 
alleles in females, while males with two alleles (ten subjects only) had the lower levels of 
obesity.  The frequency of hypertension did not differ by number of APOL1 alleles in females, 
while, among males, it was apparently highest in those with a single APOL1 risk allele, 
although this was not significant (p=0.101). The data also hint at an additive model for 
cardiovascular deaths in males, although it was not significant (p=0.138), and conversely for 
deaths of misadventure.  
Table 3 shows the kidney features of subjects aged 18 to 67 years.  In females and males 
kidney weight was lowest in people with two APOL1 risk alleles.  As expected, [19, 13], 
females had fewer nephrons than males, by about 15% for non-AAs and 10% for AA.   In AA 
females there was no difference in Nglom according to APOL1 risk alleles, while Nglom tended 
to be higher in males with APOL1 risk alleles.  Aggregate Vglom in females tended to be 
smaller than in males, while the lowest Vglom value in both sexes was in those with two risk 
alleles. However, none of these associations was significant, individually, or with Bonferroni 
correction. Furthermore, proportions of sclerosed glomeruli, degree of cortical fibrosis and 
intimal thickening in remote resistance vessels (ItR) and in capacitance vessels (ItC) did not 
differ significantly by APOL1 risk allele profile  
Although Nglom and Vglom were not significantly correlated with APOL1 profiles when all ages 
were considered together, there were apparent differences in the relationships of each to 
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age.  Tables 4A and 4 B show these data for females and males.  The data suggest higher 
baseline values of Nglom in young “APOL1 positive” (one or two risk alleles as a group) AA 
subjects, and a ranked order of glomerular “loss” with increasing age by number of APOL1 
risk alleles in AA.  The decrease is significant in females with two APOL1 risk alleles, and but 
not in males with two risk alleles, due to the small sample size (n=10).   A gradient is also 
suggested in APOL1 positive AA females and males.  Vglom increased with age in all female AA 
risk allele groups, without substantial differences between them.  However, in males with 
two risk alleles, Vglom rose sharply from an apparently lower value in young adult life to 
higher values in middle age, compared with those with no risk alleles, while the pattern in 
those with one risk allele was arguably intermediate.   
Figures 2A and 2B illustrate these phenomena over a more uniform age range. Table 5 
shows changes expressed in absolute values, as well as in fractional changes. These 
approaches give internally consistent results. The age-related reductions in Nglom were 
significant in AA subjects with two risk alleles, with one or two alleles, and in those with two 
G2 risk alleles (although there are only 5 subjects in this group).  Age-related increases in 
Vglom were significant in those with one risk allele, two risk alleles, and with one or two risk 
alleles, and, marginally in those with G1/WT and G2/G2 profiles.   
The data in Table 5 suggest an inverse correlation between changes in Nglom and Vglom. The 
relationship between the fractional change is significant by non-parametric (Kendall Tau) 
testing when the G2/G2 group (5 subjects only) is included (coefficient -0.73, p=0.0197), but 
not when that group is excluded (coefficient -0.33, p=0.215). 
However, the predicted age-related changes in Nglom and Vglom were BMI dependent.  Figure 
3 shows data for each AA APOL1 risk profile group of 20 or more subjects, divided around 
their group-specific BMI medians.  These median BMIs were all below the threshold for 
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obesity (>30 kg/m2).  Age-related decrements in Nglom were only significant in AA risk allele 
positive subjects with BMIs greater than their group medians.  The significance of age-
related Vglom increments associated with one or two APOL1 risk alleles was enhanced by 
higher BMIs.   BMI was not a significant independent predictor of Nglom in AA females or 
males, regardless of APOL1 profiles, but addition of age*BMI interaction terms modestly 
improved the explained variance of Nglom in females with two risk alleles.  BMI was an 
additional independent risk factor for Vglom in AA females with one risk allele (p=0.039), and 
BMI*age interaction term modestly improved the explained variance of Vglom in females with 
one and two risk alleles.     
The age-related decrease in Nglom in APOL1 positive people could not be readily attributed to 
hypertension or cardiovascular disease.  Figures 4A and 4B show similar trends in APOL1 
positive subjects without hypertension and without a cardiovascular cause of death.   
 
Discussion 
This is the largest study of microanatomy in kidneys of AA without renal disease at autopsy, 
and it is the only one in which associations with APOL1 risk alleles have been evaluated. 
The similarity of the APOL1 risk allele frequencies to those of ARIC enrolees suggests that 
there is little segregation of particular APOL1 genotypes among the AA undergoing autopsy 
in our series. However, the higher proportions of APOL1 risk allele-negative AA males with 
deaths of misadventure, and the trend towards lower ages at deaths of APOL1 positive 
females hint at some contribution of APOL1 risk alleles to risk of natural death.    
Our data suggest that certain characteristics are associated with APOL1 risk alleles in AA.  
Females with two risk alleles tended towards lower weight, BMI and levels of obesity than 
other AA females, and both females and males with two risk alleles had lower kidney weight 
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than other AA.  Furthermore, starting from an apparently higher baseline level of Nglom in 
early adult life, AAs with two APOL1 risk alleles had an apparent loss of nephrons with 
increasing age over the next four decades.   APOL1 risk alleles were also associated with 
smaller average Vglom in early adult life as well as with more pronounced increases in Vglom 
with age.   These phenomena were dependent on, or were enhanced by, higher BMIs.  The 
trends to smaller body size, kidney size, and glomerular volume in APOL1 homozygotes are 
compatible with our observations in autopsy subjects from Senegal in western Africa [20], a 
region with a high prevalence of APOL1 variants [21].  
Our data do not suggest that coexisting hypertension was the major driver of age-related 
changes in Nglom in subjects with two APOL1 risk alleles.  APOL1 positive females did not have 
more hypertension than those without APOL1 risk alleles, while the apparently higher levels 
in males were not significant.  Furthermore, APOL1 positive AAs without hypertension or 
cardiovascular deaths also tended towards reductions in Nglom with age.  However, it is likely 
that age related reductions in Nglom can predispose to hypertension and cardiovascular risk, 
as well as renal disease, as discussed below.  
Although the age-related trends in Nglom and Vglom are derived from a cross-sectional study, 
they probably reflect changes as an individual ages.  Non-AAs and APOL1 risk allele negative 
AAs appeared to have minimal loss of glomeruli with age up through their mid-50s, while 
some risk allele positive AAs had lower Nglom in the first 38 years of adult life. Those with 
two APOL1 risk alleles “lost” a predicted average of about 350,000 nephrons per single 
kidney over that interval, and those with one or two alleles lost about 300,000 per single 
kidney.  These are significant decrements in view of the mean single kidney nephron count 
of about 900,000 [13].   The data suggest far more serious age-related decrements of Nglom 
in G2/G2 subjects, but the numbers are very small.  We could not detect, but cannot 
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exclude, an association of these age-related changes with accelerated processes of 
glomerulosclerosis, cortical scarring or vascular change. Although extrapolations to kidney 
disease are hazardous, these findings are compatible with those of Larsen et al, who found, 
in renal biopsies in AA with arteriolarnephrosclerosis, that a relative lack of obsolescent 
glomeruli, greater degrees of solidified and disappearing glomerulosclerosis, as well as less 
arteriolar change, distinguished those with two APOL1 risk alleles from those with no risk 
alleles [22].    
Age-related reductions in Nglom and exacerbated increases in Vglom in APOL1 risk allele 
positive subjects appear to be linked. This mimics the strong inverse correlation between 
Nglom and Vglom seen in all groups in this autopsy series [19, 13].  These changes could reflect 
compensatory hypertrophy of remaining glomeruli in the setting of progressive nephron 
deficiency, or glomerular loss due to intrinsic glomerular volume expansion placing glomeruli 
at extra risk for glomerulosclerosis [15].  In either scenario the initially smaller glomeruli in 
APOL1 positive people might be at accentuated risk for damage from excessive hypertrophy.   
Furthermore, a recent study describes the influence of APOL1 risk variants on enhanced 
podocyte necrosis through compromised lysosomal membrane permeability [23].  Much 
remains to be explored in this area, including, the full degree of heterogeneous individual 
glomerular enlargement that the estimate of average Vglom disguises [17, 24], and indices of 
podocyte number and density in the younger and older at-risk subjects [25] in the various 
APOL1 subgroups. 
This series is not a resource for the study of kidney disease, because such subjects were 
deliberately excluded. However, our findings might flag mechanisms of APOL1-mediated 
susceptibility to renal disease.  Accentuated loss of Nglom with age in AA might contribute to 
earlier expression and more rapid progression of renal disease with protracted ageing 
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and/or with additional nephropathic insults, in a two-strike or multi-determinant disease 
model.  This scenario is proposed for renal disease associated with sickle cell disease, with 
collapsing nephropathy associated with lupus or HIV and with compromised graft survival 
after transplantation [4-9].  APOL1 risk variants are associated with earlier age of onset and 
progression to renal failure of subjects with FSGS, and prospective studies in the African 
American Study of Kidney Disease (AASK) and Chronic Renal Insufficiency (CRIC) cohorts 
show that carriage of two APOL1 risk variants is associated with more rapid progression to 
clinical endpoints in persons with renal insufficiency at study entry [2,3,5,7,8].   Moreover, 
AA participants without renal disease on enrolment in the ARIC study were more likely to 
develop CKD and to progress to renal failure if they had two APOL1 risk alleles, compared to 
those with no alleles or one allele [5].  
We could find no reports of exacerbation of APOL1-associated kidney disease by higher 
BMIs.   If confirmed, this constitutes additional arguments for intensified surveillance of 
APOL1 positive AAs, and incentives for them to remain relatively lean.  It is noteworthy that 
the levels of BMI associated with significant age-related changes in Nglom and Vglom in this 
study were well below those defining “obesity” (>30 kg/m2).  
Our data hint at that hypertension and cardiovascular deaths might be higher in male AA 
with APOL1 risk alleles.  Ito et al. reported association of two APOL1 risk alleles (OR~2) with 
atherosclerotic events in the Jackson Heart Study, with replication in the Women’s Health 
Initiative (WHI) study [26], although this was not replicated in the large Systolic Blood 
Pressure Intervention Trial [27] . Numerous GWAS and admixture linkage mapping studies 
have not identified chromosome 22 as a locus for systolic blood pressure or hypertension, 
suggesting that APOL1 variants probably do not contribute to primary hypertension.  
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Retrospective genetic testing of additional stored autopsy samples from AA with clear 
medical histories relating to hypertension, renal disease and cause of death could confirm or 
refute our results.   
Strengths of this report are the unique study sample and approach.  The duration of the 
sample collection (more than 10 years), the ethical considerations, and the tedious nature of 
the measurements, all weigh against its being repeated in this fashion.  
There are several limitations in this study.  The subjects constitute a convenience sample, 
selected for autopsy on medical and legal grounds, with a broad set of indications and 
underlying and coexisting conditions, ranging from deaths of misadventure to deaths with 
hypertension and cardiovascular disease.  In addition, numbers of subjects with G1/G2, 
G1/G1 and G2/G2 profiles, and of males with any combination of two risk alleles are small.   
These factors, plus the dominance of females among those with two risk alleles, all pose 
analytic problems.   Furthermore, the use of Vglom, which is an average value of glomerular 
volumes for a given kidney, provides no indication the variability in volumes of individual 
glomeruli within a given subject [13,16,17,18,24].   An additional caution is the inference 
that data on different people at different ages on a cross-sectional study, necessarily 
represent probable changes in an individual followed over a lifetime.   
Despite these important limitations, this autopsy cohort has provided a unique histological 
resource. Findings of nephron loss in a setting of certain APOL1 risk profiles and 
compensatory or causal nephron hypertrophy should provoke and direct further 
investigations.  Development of non-invasive techniques to assess glomerular number and 
glomerular volume in living humans will greatly advance progress in this important field.  
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Concise Methods  
Autopsy cohort. The right kidney was collected from 191 AA and 146 non-AA, without known 
renal disease, during autopsies conducted to investigate sudden or unexpected death, 
between 1998 and 2005, at the University of Mississippi Medical Center, Jackson, MS, USA.  
Subject selection and specimen collection have been previously described [15].  Race was 
ascertained from medical records, next-of-kin or the investigating pathologist. Subjects with 
known renal disease, with kidneys of significantly unequal size, and with scarred or 
contracted kidneys were specifically excluded, as were two subjects with unsuspected focal 
segmental glomerulosclerosis subsequently identified on histopathologic examination.  
Causes of death were documented and medical records were reviewed for a history of 
hypertension. Clinical and demographic characteristics were obtained from University of 
Mississippi Medical Centre records. Approval was obtained from the Institutional Review 
Board of the University of Mississippi Medical Center and the Human Research Ethics 
Committee of Monash University, Victoria, Australia, and consent provided by next of kin.  
 
Stereology. Kidney tissue was sent to Monash University for stereological estimation of Nglom 
and Vglom and assessment of other morphological parameters. Nglom and Vglom were 
estimated using the physical disector/fractionator combination as previously described 
[28,19,29].  In brief, perfusion-fixed kidneys were sampled to provide an isotropic, uniform 
random sample of tissue blocks.  These blocks were embedded in glycolmethacrylate and 
then exhaustively sectioned at 20µm.  Every tenth and eleventh sections (a section pair) 
were then stained with PAS, and glomeruli in identical fields in each section pair were 
counted using the disector principle [30].  Stereological point counting at the same time on 
the same sampled fields allowed the calculation of Vglom. 
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Genetic analysis.  DNA was isolated from formalin-fixed, paraffin-embedded tissue as 
previously described [31] .Genetic analysis was carried out under a protocol approved by the 
NIDDK Institutional Review Board (94-DK-0133). APOL1 risk alleles were genotyped using 
TaqMan assays (ABI, Foster City, CA). The APOL1 G1 allele was defined as the presence of 
the p.S342G variant (rs73885319A>G) and the G2 allele was defined as the deletion of 
p.N388Y389 (rs71785313 TTATAA/-). Genotyping of renal tissue was successfully performed 
on 188 AA and 144 non-AA of the autopsy cohort.  
Statistical analysis. Variables were summarized using mean (standard deviation), geometric 
mean (95% confidence interval) or percent and presented in four groups, non-AA without 
risk alleles and AA with 0, 1 or 2 risk alleles. Analyses of group data were performed in Stata 
13.1 (StataCorp. 2013. Stata: Release 13. Statistical Software. College Station, TX: StataCorp 
LP) using linear regression, logistic regression and chi-squared tests. Various transformations 
were applied to certain variables to optimise the normalcy of their distributions, and when 
applied, are specified in the legends of the data in the relevant tables.  Allele group differences 
were tested using recessive (two vs none or one risk alleles), dominant (one or two risk 
alleles vs none) and additive (2>1>0 risk alleles) models, including adjustments for sex and 
age. Two-sided Fisher’s exact tests were used to evaluate if genotype frequencies were in 
Hardy-Weinberg equilibria.  
 
 
Renal and related physical characteristics and renal morphologic features were analysed in 
the context of APOL1 risk alleles for subjects aged 18 to 67 years old at time of death.   Only 
four AA in the entire series were older than this. The predicted annual changes of Nglom and 
Vglom in AA groups with various combinations of APOL1 risk alleles were evaluated over ages 
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20 to 57 years, a range over which most APOL1 profile groups had a reasonable 
representation.    
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Figure legends 
 
 
Figure 1. Proportions of obesity, hypertension, cardiovascular deaths and deaths by 
misadventure in African Americans age 18 to 67 years at autopsy, by sex and number of 
APOL1 risk alleles, adjusted for age. 
P1; P-value of F-test for linear trend (Additive model) from age-adjusted logistic regression 
P2; P-value for the Dominant model from age-adjusted logistic regression 
 
 
Figure 2. Age-related change in Nglom (A) and Vglom (B) at autopsy age 20 to 57 years, by 
race, number of APOL1 risk allele profiles and sex, adjusted for age.  
Nglom; estimated total number of glomeruli per kidney 
Vglom; estimated mean glomerular volume (µm
3x106) 
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Figure 3.  Comparison of fractional annual age changes at autopsy age 20 to 57 years in 
Nglom and Vglom, in those with BMI ≥ and < their group median, by race and APOL1 risk 
allele profiles, adjusted by age and sex. 
The group median BMI for AA with no risk alleles was 28.8 kg/m2 and for AA in groups with risk alleles it 
ranged from 25.6 to 27.6 kg/m2.   
Nglom; estimated total number of glomeruli per kidney 
Vglom; estimated mean glomerular volume (µm
3x106) 
AA; African American 
 
 
 
 
 
 
 
Figure 4. Age-related change in Nglom in African Americans with one or two APOL1 risk 
alleles at autopsy age 18 to 67 years, without hypertension (A) and without a  
cardiovascular cause of death (B), adjusted for age and sex.  
Nglom; estimated total number of glomeruli per kidney 
N; number of subjects 
P; P-value of modelled age  
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Table 1. African American APOL1 genotype and risk allele frequencies, in the ARIC and 
current studies. 
 
Characteristic 
ARIC study [5], 
45-64 yrs, 
n=3,067 
Current study, ≥18 yrs 
All 
n=159  
Females 
n=76  
Males 
n=83  
Number of APOL1 risk alleles, n (%)     
None 1,270 (41.4) 61(38.4) 25 (32.9) 36 (43.4) 
One 1,393 (45.4) 68 (42.8) 31 (40.8) 37 (44.6) 
Two 404 (13.2) 30 (18.9) 20 (26.3) 10 (12.0) 
Frequencies of APOL1 risk alleles      
G1 0.22 0.23 0.28 0.18 
G2 0.13 0.17 0.18 0.16 
 Frequencies of APOL1 genotypes, n (%)     
WT/WT 1,270 (41.4) 61 (38.4) 25 (32.9) 36 (43.4) 
WT/G1 859 (28.0) 36 (22.6) 16 (21.1) 20 (24.1) 
WT/G2 534 (17.4) 32 (20.1) 15 (19.7) 17 (20.5) 
G1/G2 201 (6.6) 13 (8.2) 9 (11.8) 4 (4.8) 
G1/G1 153 (5.0) 12 (7.5) 9 (11.8) 3 (3.6) 
G2/G2 50 (1.6) 5 (3.1) 2 (2.6) 3 (3.6) 
HWE P 0.884 0.653 0.57 1.0 
WT; Wildtype (no APOL1 risk alleles) 
HWE P; P-value for Hardy-Weinberg Equilibrium, tested with two-sided Fisher’s exact tests 
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Table 2.  Characteristics of subjects at autopsy age 18 to 67 years, by race, sex and number of APOL1 risk alleles.  
Risk Allele Profile n 
Age range, 
yr 
Age, yr, 
Mean (SD) 
Height, 
cm, 
Mean (SD) 
Weight, kg 
Gmean 
 (95% CI) 
BMI, kg/m2, 
Gmean 
(95% CI) 
BMI ≥30, 
% (n) 
Hyper-
tension, 
% (n) 
Cardio-
vascular 
death, 
% (n) 
Death by 
 mis- 
adventu
re, 
% (n) 
Non-African Americans,  No risk alleles 
Females 46 18 to 65 42 (10.4) 163 (8.9) 75.1 (69.9-80.6) 28.4 (26.4-30.6) 35% (16) 23% (10) 24% (11) 26% (12) 
Males 79 18 to 67 44 (13.0) 174 (9.2) 88.4 (82.5-94.6) 29.2 (27.4-31.0) 43% (34) 39% (30) 35% (27) 34% (27) 
African American  Females 
No risk alleles 25 21 to 67 45 (12.0) 166 (8.8) 82.9 (71.9-95.5) 30.4 (26.4-34.9) 60% (15) 58% (14) 24% (6) 12% (3) 
One risk allele 31 19 to 57 39 (9.9) 164 (7.3) 85.1 (73.9-98.0) 31.8 (27.9-36.3) 45% (14) 48% (15) 39% (12) 13% (4) 
Two risk alleles 18 20 to  57 38 (11.9) 162 (7.3) 75.0 (65.9-85.2) 28.4 (25.3-32.0) 28% (5) 44% (8) 19% (3) 17% (3) 
One or two risk alleles 49 19 to 57 38 (10.6) 163 (7.3) 81.2 (73.5-89.7) 30.5 (27.8-36.1) 39% (19) 47% (23) 32% (15) 14% (7) 
P, Recessive model   0.196 0.381 0.189 0.240 0.091 0.939 0.485 0.870 
P, Dominant model   0.020 0.268 0.646 0.841 0.104 0.954 0.190 0.757 
P, Additive model   0.032 0.249 0.269 0.388 0.047 0.934 0.833 0.949 
African American Males 
No risk alleles 36 18 to 67 41 (13.3) 179 (9.7) 85.3 (78.4-92.8) 26.7 (24.6-29.1) 31% 11) 51% (18) 37% (13) 25% (9) 
One risk allele 36 19 to 65 44 (12.4) 179 (7.7) 89.5 (81.9-97.9) 28.1 (25.9-30.6) 31% (11) 74% (26) 53% (19) 19% (7) 
Two risk alleles 10 20 to 51 37 (10.9) 181 (8.2) 82.0 (67.4-99.8) 25.1 (21.5-29.5) 10% (1) 40% (4) 60% (6) 10% (1) 
One or two risk alleles 46 19 to 65 42 (12.3) 179 (7.8) 87.8 (81.2-95.0) 27.4 (25.5-29.5) 26% (12) 67% (30) 54% (25) 17% (8) 
P, Recessive model   0.193 0.363 0.425 0.217 0.182 0.509 0.199 0.301 
P, Dominant model   0.636 0.992 0.581 0.575 0.655 0.183 0.138 0.425 
P, Additive model   0.355 0.451 0.609 0.397 0.198  0.862 0.138  0.293 
IQR; inter-quartile range 
SD; standard deviation 
Gmean; geometric mean 
CI; confidence interval 
Recessive model, 2 vs 0/1 risk alleles; Dominant model, 2/1 vs 0 risk alleles; Additive model, 2>1>0 risk alleles.  
P; P-value; logistic regression (weight and height were log transformed) was used to test Recessive and Dominant models; logistic regression and an F-test for linear trend 
was used for Additive models. All tests included adjustment for age. Significance (P(α) 0.05) is shown in bold.   
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Table 3.  Kidney features in subjects at autopsy age 18 to 67 years, by race, sex and number of APOL1 risk alleles.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SD; standard deviation 
Nglom; estimated total number of glomeruli per kidney 
Vglom; estimated mean glomerular volume (µm
3x106) 
Gmean; geometric mean 
CI: confidence interval 
GS; glomerular sclerosis 
Cort fib; cortical fibrosis (percent of cortex fibrosed) 
ItR; intimal thickening ratio in remote resistance vessels 
ItC; intimal thickening ratio in close compliance vessels 
Recessive model, 2 vs 0/1 risk alleles; Dominant model, 2/1 vs 0 risk alleles; Additive model, 2>1>0 risk alleles.  
P; P-value; linear regression of log (kidney weight, Vglom) or square root(Nglom, GS, Cort fib, ItR, ItC) transformed continuous variables were performed for Recessive and 
Dominant models; Additive models used an F-test for linear trend test. All tests included adjustment for age. 
Risk Allele Profile N 
Age range, 
yr 
Kidney 
weight, 
Mean (SD) 
Nglom, 
Mean  (SD) 
Vglom, 
Gmean  
(95% CI) 
GS %, 
Gmean 
(95% CI) 
Cort fib%, 
Gmean 
(95% CI) 
 
ItR, 
Gmean 
(95% CI) 
ItC, 
Gmean 
(95% CI) 
Non-African Americans, no risk alleles 
Females 46 18 to 65 159.6 (47.0) 865,190 (298,875) 6.4 (5.7-7.2) 1.5 (1.1-2.1) 2.8 (2.1 -3.8) .05 (.03-.06) .09 (.07-.12) 
Males 79 18 to 67 191.2 (49.0) 993,632 (314,664) 6.5 (6.0-7.0) 1.7 (1.3-2.2) 3.4 (2.7-4.2) .07 (.05-.08) .10 (.09 -.13) 
African American Females 
No risk alleles 25 21 to 67 164.6 (41.9) 888,707 (204,496) 7.2 (6.2-8.3) 2.5 (1.7-3.7) 4.5(3.3-6.3) .06 (.04-.10) .11(.08-.14) 
One risk allele 31 19 to 57 165.8 (49.5) 891,476 (278,633) 7.2 (6.3-8.3) 2.7 (1.7-4.2) 4.5 (2.9-6.8) .06 (.04-.09) .11 (.08-.14) 
Two risk alleles 18 20 to  57 149.3 (31.9) 850,073 (172,254) 6.8 (5.8-8.1) 2.0 (1.1-3.6) 3.0 (1.6-5.7) .07 (.04-.12) .10 (.07-.15) 
One or two risk alleles 49 19 to 57 159.8 (44.3) 876,267 (243,799) 7.1 (6.4-7.9) 2.4 (1.7-3.4) 3.8 (2.7-5.4) .07 (.05-.09) .11 (.08-.14) 
P, Recessive model   0.232 0.579 0.757 0.295 0.790 0.849 0.306 
P, Dominant model   0.576 0.483 0.789 0.221 0.630 0.671 0.136 
P, Additive model   0.281 0.457 0.959 0.177 0.662 0.722 0.138 
African American Males 
No risk alleles 36 18 to 67 181.8 (41.4) 928,543 (328,676) 7.8 (7.0-8.7) 2,4 (1.5-3.9) 3.7 (2.4-5.7) .11 (.08-.14) .10 (.07-.15) 
One risk allele 36 19 to 65 187.6 (47.6) 972,960 (351,069) 8.6 (7.7-9.6) 2.9 (1.9-4.3) 4.3 (3.1-5.9) .09 (.07-.12) .11 (.08-.14) 
Two risk alleles 10 20 to 51 178.4 (50.8) 1,117,034 (347,933) 7.1 (5.5-9.2) 1.2 (0.5-3.1) 2.1 (0.9-4.5) .04 (.02-.12) .07(.04-.14) 
One or two risk alleles 46 19 to 65 185.6 (47.9) 1,004,281 (351,684) 8.2 (7.4-9.1) 2.4 (1.7-3.5) 3.6 (2.7-4.9) .08 (.06-.10) .10 (.08-.12) 
P, Recessive model   0.774 0.206 0.299 0.544 0.785 0.695 0.392 
P, Dominant model   0.836 0.268 0.524 0.535 0.900 0.405 0.854 
P, Additive model   0.865 0.156 0.513 0.477 0.789 0.544 0.441 
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Table 4A. Regression characteristics of predictions of average annual changes in Nglom 
versus age, around specified age ranges, by race, sex and number of APOL1 risk alleles.   
 
Risk Allele Profile 
Age range, 
yr 
N Intercept Coefficient  (95%CI) P 
Non-African Americans, no risk alleles 
Females 18 to 65 46 1,083,710 -5,171 (-13,747 to 3,405) 0.231 
Males 18 to 67 79 968,984 648 (4,851 to 6,147) 0.815 
African American Females 
Zero risk alleles 21 to 67 25 825,386 1,407 (-5,942 to 8,756) 0.696 
One risk allele 19 to 57 31 1,083,922 -4,971 (-15,481 to 5,538) 0.341 
Two risk alleles 20 to 57 18 1,108,733 -6,898 (-13,699 to -126) 0.046 
One or two risk alleles 19 to 57 49 1,094,762 -5,710 (-12,272 to 852) 0.087 
African American Males 
Zero risk alleles 18 to 67 36 1,108,345 -4,418 (-12,915 to 4,078) 0.298 
One risk allele 19 to 65 36 1,248,072 -6,316 (-15,966 to 3,333) 0.192 
Two risk alleles 20 to 51 10 1,596,207 -13,128 (-36,728 to 10,471) 0.235 
One or two risk alleles 19 to 65 46 1,348,860 -8,200 (-16,516 to 116) 0.053 
Nglom; estimated total number of glomeruli per kidney 
CI; Confidence interval 
P; P-value of linear regression 
 
 
Table 4B. Regression characteristics of predictions of average annual changes in Vglom 
versus age, around specified age ranges, by race, sex and number of APOL1 risk alleles. 
 
Risk Allele Profile 
Age range, 
yr 
N Intercept Coefficient  (95%CI) P 
Non-African Americans, no risk alleles 
Females 18 to 65 46 5.35 0.04 -(0.04 to 0.11) 0.335 
Males 18 to 67 79 5.55 0.03 (-0.01 to 0.07) 0.163 
African American Females 
Zero risk alleles 21 to 67 25 8.49 -0.02 (-0.11 to 0.07) 0.654 
One risk allele 19 to 57 31 4.04 0.10 (-0.01 to 0.21) 0.087 
Two risk alleles 20 to 57 18 4.15 0.08 (-0.02 to .18) 0.106 
One or two risk alleles 19 to 57 49 3.90 0.10 (0.02 to 0.17) 0.017  
African American Males 
Zero risk alleles 18 to 67 36 8.27 -0.001 (-0.08 to 0.07) 0.976 
One risk allele 19 to 65 36 7.36 0.04 (-0.04 to 0.11) 0.324 
Two risk alleles 20 to 51 10 2.03 0.15 (-0.02 to 0.33) 0.083 
One or two risk alleles 19 to 65 46 5.93 0.07 (-0.001 to 0.13) 0.054 
Vglom; estimated mean glomerular volume (µm
3x106) 
CI; Confidence interval 
P; P-value of linear regression 
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Table 5.   Predicted annual and fractional changes in Nglom and Vglom versus age at autopsy 
age 20 to 57 years, by race and APOL1 risk allele profiles, adjusted for age and sex                                                                                                                                               
  Absolute change  Fractional change  
Risk Allele Profile N 
Nglom, 
Coefficient (95% CI) 
P 
Nglom, 
Ratio (95%CI) 
P 
Non-African Americans,  
No risk alleles 
106 
340 
(-5,530 to 6,210) 
0.909 
0.0003 
(-0.0065 to 0.0072) 
0.923 
African Americans,  
No risk alleles 
48 
-1,480 
(-10,267 to 7,306) 
0.736 
-0.0018  
(-0.0114 to 0.0079) 
0.711 
African Americans,  
One risk allele 
61 
-5,885 
(-14,831 to 3,060) 
0.193 
-0.0059  
(-0.0156 to 0.0039) 
0.232 
African Americans,  
Two risk alleles 
28 
-8,834 
(-16,676 to -791) 
0.033 
-0.0088  
(-0.0164 to -0.0011) 
0.027 
African Americans, 
One or two risk alleles 
89 
-7,272 
-13,498 to -1,046) 
0.023* 
-0.0074  
(-0.0140 to -0.0008) 
0.029 
 
African Americans, 
GI/WT 
32 
-6,204 
(-19,741 to 7,334) 
0.356 
-0.0049  
(-0.0193 to 0.0098) 
0.500 
African Americans, 
G2/WT 
29 
-4,216 
(-16,201 to 7,768) 
0.476 
-0.0058  
(-0.0193 to 0.0079) 
0.388 
African Americans, 
G1/G2 
12 
2,114 
(-8,527 to 12,755) 
0.664 
0.0008  
(-0.0113 to 0.0130) 
0.885 
African Americans, 
G1/G1 
11 
-5,618 
(-14,473 to 3,237) 
0.182 
-0.0064  
(-0.0164 to 0.0038) 
0.186 
African Americans, 
G2/G2 
5 
-37,636                                           
(-64,544 to -10,729) 
0.027 
-0.0291 
(-0.0541 to -0.0034) 
0.040 
  
Vglom, 
Coefficient (95%CI) 
 
Vglom, 
Ratio (95%CI) 
 
Non-African Americans,  
No risk alleles 
106 
0.02 
(-0.02 to 0.07) 
0.341 
0.0042 
(-0.0025 to 0.0110) 
0.220 
African Americans,  
No risk alleles 
48 
0.04 
(-0.04 to 0.12) 
0.338 
0.0053  
(-0.0051 to 0.0158) 
0.308 
African Americans,  
One risk allele 
61 
0.09 
(0.01 to 0.16) 
0.024* 
0.0108  
(0.0014 to 0.0202) 
0.025 
African Americans,  
Two risk alleles 
28 
0.10 
(0.02 to 0.19) 
0.017* 
0.0142  
(0.0035 to 0.0251) 
0.011* 
African Americans, 
One or two risk alleles 
89 
0.10 
(0.04 to 0.16) 
 
0.001* 
0.0129  
(0.0060 to 0.0198) 
<0.001* 
African Americans, 
GI/WT 
32 
0.11 
(0 to 0.22) 
0.050 
0.0143  
(0.0003 to 0.0284) 
0.045 
African Americans, 
G2/WT 
29 
0.06 
(-0.06 to 0.18) 
0.317 
0.0061  
(-0.0073 to 0.0196) 
0.359 
African Americans, 
G1/G2 
12 
0.02 
(-0.13 to 0.17) 
0.792 
1.00056  
(-0.0164 to 0.0178) 
0.943 
African Americans, 
G1/G1 
11 
0.11 
(-0.03 to 0.24) 
0.112 
1.014575 
(-0.0028 to 0.0322) 
0.089 
African Americans, 
G2/G2 
5 
0.13 
(0 to 0.26) 
0.051 
0.0264  
(0.0047 to 0.0484) 
0.034 
Nglom; estimated total number of glomeruli per kidney (log transformed for fractional estimation) 
Vglom; estimated mean glomerular volume (µm
3x106) (log transformed for fractional estimation) 
CI; Confidence interval 
P; P-value of linear regression 
*Remain significant after Bonferroni corrections for multiple (two) comparisons) 
 
 
 
 
 
